23 C
New York
Sunday, June 14, 2026

Tag: regulatory approval

newssourceFORcompanyinformationcontent1marketreleases

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS...

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...

Terrestrial Energy Selected for DOE Office of Nuclear Energy Advanced Reactor Pilot Program for Accelerated Development

Advanced Reactor Pilot Program launched by DOE to expedite authorization and commercialization of advanced nuclear reactor designs

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10...

FOKUS MINING TO ACQUIRE KEY LAND PACKAGE FROM VISIBLE GOLD MINES ALONG CADILLAC-LARDER LAKE FAULT

TSX.V: FKM          OTCQB: FKMCF         Frankfurt: F7E1    (All amounts expressed in Canadian dollars unless otherwise stated) ROUYN-NORANDA, QC, Aug. 12, 2025 /CNW/ - Fokus Mining Corporation...

Cardinal Health announces the addition of Solaris Health, the country’s leading urology MSO, to The Specialty Alliance

Adds over 750 providers to Cardinal Health's multi-specialty MSO platform, The Specialty AllianceJoins with recent urology acquisitions to bolster The Specialty Alliance's leadership in...

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies | DelveInsight

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...

Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates

BRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for...

Lincoln Educational Services Reports Second Quarter Results and Increases Outlook for Full Year 2025

Conference Call Today at 10:00 a.m. Eastern Daylight Time 
Conference Call Today at 10:00 a.m. Eastern Daylight Time

Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter,...

2025 Report: “PurDentix Reviews and Complaints” Surge Reflects Growing Curiosity Around Oral Microbiome Supplements

Consumer Search Data Reveals Expanding Curiosity Around Oral Probiotics and Ingredient Transparency in 2025 
Consumer Search Data Reveals Expanding Curiosity Around Oral Probiotics and Ingredient Transparency in 2025

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRegulatory approval

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers